209 related articles for article (PubMed ID: 32687856)
21. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.
Tawk B; Wirkner U; Schwager C; Rein K; Zaoui K; Federspil PA; Adeberg S; Linge A; Ganswindt U; Hess J; Unger K; Tinhofer I; Budach V; Lohaus F; Krause M; Guberina M; Stuschke M; Balermpas P; Rödel C; Grosu AL; Schäfer H; Zips D; Combs SE; Pigorsch S; Zitzelsberger H; Baumeister P; Kirchner T; Bewerunge-Hudler M; Weichert W; Hess J; Herpel E; Belka C; Baumann M; Debus J; Abdollahi A;
Int J Cancer; 2022 Feb; 150(4):603-616. PubMed ID: 34648658
[TBL] [Abstract][Full Text] [Related]
22. Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer.
Egyud M; Sridhar P; Devaiah A; Yamada E; Saunders S; Ståhlberg A; Filges S; Krzyzanowski PM; Kalatskaya I; Jiao W; Stein LD; Jalisi S; Godfrey TE
Head Neck; 2019 May; 41(5):1351-1358. PubMed ID: 30554450
[TBL] [Abstract][Full Text] [Related]
23. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumour DNA detects somatic variants contributing to spatial and temporal intra-tumoural heterogeneity in head and neck squamous cell carcinoma.
Payne KFB; Brotherwood P; Suriyanarayanan H; Brooks JM; Batis N; Beggs AD; Gendoo DMA; Mehanna H; Nankivell P
Front Oncol; 2024; 14():1374816. PubMed ID: 38846976
[TBL] [Abstract][Full Text] [Related]
25. Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia.
Yahya N; Linge A; Leger K; Maile T; Kemper M; Haim D; Jöhrens K; Troost EGC; Krause M; Löck S
Acta Oncol; 2022 Jul; 61(7):856-863. PubMed ID: 35657056
[TBL] [Abstract][Full Text] [Related]
26. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic value and prospects of gene mutations in circulating tumor DNA for head and neck cancer monitoring.
Yang X; Xu X; Zhang C; Ji T; Wan T; Liu W
Oral Oncol; 2022 May; 128():105846. PubMed ID: 35358785
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy in head neck cancer: ready for clinical routine diagnostics?
Tinhofer I; Staudte S; George S
Curr Opin Oncol; 2023 May; 35(3):151-157. PubMed ID: 36966499
[TBL] [Abstract][Full Text] [Related]
29. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
30. Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
Koi L; Bitto V; Weise C; Möbius L; Linge A; Löck S; Yaromina A; Besso MJ; Valentini C; Pfeifer M; Overgaard J; Zips D; Kurth I; Krause M; Baumann M
J Transl Med; 2023 Aug; 21(1):576. PubMed ID: 37633930
[TBL] [Abstract][Full Text] [Related]
31. Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN).
Galot R; Machiels JH
Cancer Treat Rev; 2020 Apr; 85():101992. PubMed ID: 32092618
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Carboplatin/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck.
Maring S; Elsayad K; Stenner M; Rudack C; Haverkamp U; Rehkämper J; Wardelmann E; Eich HT
Oncol Res Treat; 2018; 41(12):736-743. PubMed ID: 30419553
[TBL] [Abstract][Full Text] [Related]
33. Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy.
de Roest RH; Mes SW; Poell JB; Brink A; van de Wiel MA; Bloemena E; Thai E; Poli T; Leemans CR; Brakenhoff RH
Clin Cancer Res; 2019 Dec; 25(23):7256-7265. PubMed ID: 31439582
[TBL] [Abstract][Full Text] [Related]
34. Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
Galot R; van Marcke C; Helaers R; Mendola A; Goebbels RM; Caignet X; Ambroise J; Wittouck K; Vikkula M; Limaye N; Machiels JH
Oral Oncol; 2020 May; 104():104631. PubMed ID: 32169746
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients.
Clasen K; Welz S; Faltin H; Zips D; Eckert F
Strahlenther Onkol; 2022 Feb; 198(2):194-200. PubMed ID: 34671818
[TBL] [Abstract][Full Text] [Related]
36. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
37. Cell-free DNA and circulating tumor cell kinetics in a pre-clinical head and neck Cancer model undergoing radiation therapy.
Muhanna N; Eu D; Chan HHL; Douglas C; Townson JL; Di Grappa MA; Mohamadi RM; Kelley SO; Bratman SV; Irish JC
BMC Cancer; 2021 Oct; 21(1):1075. PubMed ID: 34600526
[TBL] [Abstract][Full Text] [Related]
38. Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma.
Schmidt S; Linge A; Grosser M; Lohaus F; Gudziol V; Nowak A; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baretton GB; Buchholz F; Baumann M; Krause M; Löck S;
J Mol Diagn; 2020 Jun; 22(6):801-810. PubMed ID: 32247864
[TBL] [Abstract][Full Text] [Related]
39. Plasma sICAM-1 correlates with tumor volume before primary radiochemotherapy of head and neck squamous cell carcinoma patients.
Clasen K; Welz S; Faltin H; Zips D; Eckert F
Radiol Oncol; 2022 Dec; 56(4):501-507. PubMed ID: 36503712
[TBL] [Abstract][Full Text] [Related]
40. Circulating cell-free DNA: A potential biomarker to differentiate inflammation and infection during radiochemotherapy.
Zwirner K; Hilke FJ; Demidov G; Ossowski S; Gani C; Rieß O; Zips D; Welz S; Schroeder C
Radiother Oncol; 2018 Dec; 129(3):575-581. PubMed ID: 30097252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
